Skip to main content

CORRECTION article

Front. Oncol., 16 April 2021
Sec. Cancer Molecular Targets and Therapeutics
Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.677725

Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

This article is a correction to:

  1. GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

    1. Read original article
Laurence BoothLaurence Booth1Cameron WestCameron West2Daniel Von HoffDaniel Von Hoff3Paul Dent*Paul Dent1*
  • 1Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, United States
  • 2Genzada Pharmaceuticals, Sterling, KS, United States
  • 3Translational Genomics Research Institute (TGEN), Phoenix, AZ, United States

A Corrigendum on
GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

by Booth L, West C, Hoff DV and Dent P (2020). Front. Oncol. 10:1331. doi: 10.3389/fonc.2020.01331

In the published article, there was an error in the Conflict of Interest statement. We neglected to include that the author Paul Dent, is a paid consultant and a Key Advisor for Genzada Pharmaceuticals. The correct statement appears below.

“PD has received funding support from Genzada Pharmaceuticals Inc. for these studies. CW is a paid officer of the company. DH is a paid consultant and a Key Scientific advisor to the company. PD is a paid consultant and a Key Advisor for Genzada Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: autophagy, GZ17-6.02, sarcoma, doxorubicin, CD95, death receptor

Citation: Booth L, West C, Von Hoff D and Dent P (2021) Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling. Front. Oncol. 11:677725. doi: 10.3389/fonc.2021.677725

Received: 08 March 2021; Accepted: 10 March 2021;
Published: 16 April 2021.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Booth, West, Von Hoff and Dent. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Paul Dent, paul.dent@vcuhealth.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.